(COCO) Vita Coco - Overview
Sector: Consumer Defensive | Industry: Beverages - Non-Alcoholic | Exchange: NASDAQ (USA) | Market Cap: 4.487m USD | Total Return: -59.6% in 12m
Avg Turnover: 92.6M
EPS Trend: 94.3%
Qual. Beats: 1
Rev. Trend: 94.7%
Qual. Beats: 6
Warnings
No concerns identified
Tailwinds
Leader, Pead, Tailwind, Pullback 52w, Confidence
The Vita Coco Company (COCO) is a global leader in the non-alcoholic beverage sector, specializing in the development and distribution of coconut-based products. Its portfolio includes flagship coconut water, plant-based dairy alternatives, and protein-infused fitness drinks. The company operates an asset-light business model, primarily sourcing raw materials from tropical regions like Southeast Asia and Brazil while utilizing third-party manufacturers for production.
The company reaches consumers through a multi-channel distribution strategy encompassing retail, e-commerce, and foodservice. Beyond its primary brand, Vita Coco maintains a significant presence in the private label segment, supplying store-brand coconut water to major global retailers. The coconut water category is characterized by high growth relative to traditional sodas, driven by increasing consumer demand for functional, low-sugar hydration options. For a deeper look into the companys fundamentals, consider reviewing the latest financial metrics on ValueRay.
Headquartered in New York, the firm rebranded from All Market Inc. in 2021 to align its corporate identity with its core consumer brand. It maintains a broad geographic footprint across North America, Europe, and the Asia Pacific region.
- Ocean freight rates and container availability impact gross margin volatility
- Market share gains in the branded coconut water category drive revenue
- Private label contract renewals influence long-term manufacturing capacity and scale
- Consumer shift toward natural hydration alternatives expands total addressable market
- Raw material sourcing costs in Southeast Asia affect bottom-line profitability
| Net Income: 82.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 4.89 > 1.0 |
| NWC/Revenue: 49.57% < 20% (prev 48.22%; Δ 1.35% < -1%) |
| CFO/TA 0.15 > 3% & CFO 72.6m > Net Income 82.9m |
| Net Debt (-189.0m) to EBITDA (98.2m): -1.93 < 3 |
| Current Ratio: 3.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.5m) vs 12m ago 0.83% < -2% |
| Gross Margin: 37.20% > 18% (prev 0.37%; Δ 3.68k% > 0.5%) |
| Asset Turnover: 151.0% > 50% (prev 139.4%; Δ 11.61% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.67 (Total Current Assets 449.7m - Total Current Liabilities 123.2m) / Total Assets 488.3m |
| B: 0.53 (Retained Earnings 258.5m / Total Assets 488.3m) |
| C: 0.22 (EBIT TTM 96.8m / Avg Total Assets 436.2m) |
| D: 1.90 (Book Value of Equity 259.1m / Total Liabilities 136.2m) |
| Altman-Z'' = 9.60 = AAA |
| DSRI: 1.28 (Receivables 120.8m/76.8m, Revenue 658.6m/535.2m) |
| GMI: 1.00 (GM 37.20% / 37.24%) |
| AQI: 0.77 (AQ_t 0.04 / AQ_t-1 0.05) |
| SGI: 1.23 (Revenue 658.6m / 535.2m) |
| TATA: 0.02 (NI 82.9m - CFO 72.6m) / TA 488.3m) |
| Beneish M = -2.74 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at USD 78.83 with a total of 830,717 shares traded.
Over the past week, the price has changed by -4.88%,
over one month by +11.05%,
over three months by +20.50% and
over the past year by -59.63%.
Vita Coco has received a consensus analysts rating of 3.90. Therefore, it is recommended to buy COCO.
- StrongBuy: 4
- Buy: 1
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 73.7 | -6.5% |
P/E Forward = 28.8184
P/S = 6.8123
P/B = 12.6316
Revenue TTM = 658.6m USD
EBIT TTM = 96.8m USD
EBITDA TTM = 98.2m USD
Long Term Debt = unknown (none)
Short Term Debt = 3.00k USD (from shortTermDebt, last fiscal year)
Debt = 12.9m USD (from shortLongTermDebtTotal, last quarter) (leases 12.9m already included)
Net Debt = -189.0m USD (calculated: Debt 12.9m - CCE 201.9m)
Enterprise Value = 4.30b USD (4.49b + Debt 12.9m - CCE 201.9m)
Interest Coverage Ratio = unknown (Ebit TTM 96.8m / Interest Expense TTM 0.0)
EV/FCF = 66.61x (Enterprise Value 4.30b / FCF TTM 64.5m)
FCF Yield = 1.50% (FCF TTM 64.5m / Enterprise Value 4.30b)
FCF Margin = 9.80% (FCF TTM 64.5m / Revenue TTM 658.6m)
Net Margin = 12.59% (Net Income TTM 82.9m / Revenue TTM 658.6m)
Gross Margin = 37.20% ((Revenue TTM 658.6m - Cost of Revenue TTM 413.6m) / Revenue TTM)
Gross Margin QoQ = 39.68% (prev 34.54%)
Tobins Q-Ratio = 8.80 (Enterprise Value 4.30b / Total Assets 488.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 12.9m)
Taxrate = 18.61% (6.97m / 37.4m)
NOPAT = 78.8m (EBIT 96.8m * (1 - 18.61%))
Current Ratio = 3.65 (Total Current Assets 449.7m / Total Current Liabilities 123.2m)
Debt / Equity = 0.04 (Debt 12.9m / totalStockholderEquity, last quarter 352.2m)
Debt / EBITDA = -1.93 (Net Debt -189.0m / EBITDA 98.2m)
Debt / FCF = -2.93 (Net Debt -189.0m / FCF TTM 64.5m)
Total Stockholder Equity = 326.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 19.01% (Net Income 82.9m / Total Assets 488.3m)
RoE = 25.43% (Net Income TTM 82.9m / Total Stockholder Equity 326.1m)
RoCE = 26.51% (EBIT 96.8m / Capital Employed (Total Assets 488.3m - Current Liab 123.2m))
RoIC = 21.58% (NOPAT 78.8m / Invested Capital 365.2m)
WACC = 8.54% (E(4.49b)/V(4.50b) * Re(8.56%) + D(12.9m)/V(4.50b) * Rd(0.0%) * (1-Tc(0.19)))
Discount Rate = 8.56% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 68.89 | Cagr: 0.72%
[DCF] Terminal Value 77.37% ; FCFF base≈51.5m ; Y1≈59.0m ; Y5≈86.9m
[DCF] Fair Price = 25.48 (EV 1.27b - Net Debt -189.0m = Equity 1.46b / Shares 57.1m; r=8.54% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 94.31 | EPS CAGR: 35.36% | SUE: 4.0 | # QB: 1
Revenue Correlation: 94.75 | Revenue CAGR: 12.33% | SUE: 3.36 | # QB: 6
EPS current Quarter (2026-06-30): EPS=0.54 | Chg30d=+8.05% | Revisions=+33% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.50 | Chg30d=-2.61% | Revisions=-33% | Analysts=3
EPS current Year (2026-12-31): EPS=1.78 | Chg30d=+10.13% | Revisions=+33% | GrowthEPS=+33.9% | GrowthRev=+20.6%
EPS next Year (2027-12-31): EPS=2.05 | Chg30d=+6.97% | Revisions=+33% | GrowthEPS=+15.2% | GrowthRev=+12.0%
[Analyst] Revisions Ratio: +33%